(Q47695462)

4 February 2018

title

Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein (English)

1 reference

4 February 2018

0 references

T Tachibana

1

1 reference

4 February 2018

M Kato

2

1 reference

4 February 2018

T Watanabe

3

1 reference

4 February 2018

T Mitsui

4

1 reference

4 February 2018

Y Sugiyama

5

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 June 2009

1 reference

4 February 2018

published in

Xenobiotica

1 reference

4 February 2018

volume

39

1 reference

4 February 2018

issue

6

1 reference

4 February 2018

page(s)

430-443

1 reference

4 February 2018

Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam.

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Bicalutamide: clinical pharmacokinetics and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Cimetidine and ranitidine increase midazolam bioavailability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Triazolam Kinetics: Interaction with Cimetidine, Propranolol, and the Combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Differential impairment of triazolam and zolpidem clearance by ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Database analyses for the prediction of in vivo drug-drug interactions from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Intestinal drug transporters: in vivo function and clinical importance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Interaction between FK506 and clotrimazole in a liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

A potentially hazardous interaction between erythromycin and midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Effects of metronidazole on midazolam metabolism in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

An integrated model for determining causes of poor oral drug absorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00498250902846252

10.1080/00498250902846252

21 January 2018

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018